Actively Recruiting
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Led by Bristol-Myers Squibb · Updated on 2025-11-20
1182
Participants Needed
3
Research Sites
519 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to provide information on maternal, fetal, and infant outcomes following exposure of ozanimod during pregnancy so that participants and physicians can weigh the benefits and risks of exposure to the pharmaceutical during pregnancy and make informed treatment decisions.
CONDITIONS
Official Title
A Study on the Safety of Ozanimod Exposure in Pregnant Women and Their Offspring
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Multiple sclerosis (MS)
- Currently or recently pregnant
- Reside in the United States, Canada or Germany.
You will not qualify if you...
- Exposure to other S1P therapies, cladribine, or mitoxantrone during the first trimester.
- Other protocol-defined inclusion/exclusion criteria apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 3 locations
1
Evidera INC.
Bethesda, Maryland, United States, 20814
Actively Recruiting
2
Evidera
Bethesda, Maryland, United States, 20814
Actively Recruiting
3
Marienhospital Herne, Klinikum Der Ruhr-Universitaet Bochum
Herne, Germany, 44625
Actively Recruiting
Research Team
B
BMS Study Connect Contact Center www.BMSStudyConnect.com
CONTACT
F
First line of the email MUST contain the NCT# and Site #.
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here